Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 Black Phoenix Black Phoenix +336.38%
#4 aPriori aPriori +129.43%
#5 Bedrock Bedrock +68.55%
#6 Cysic Cysic +48.18%
#7 Prom Prom +41.94%
#8 Playnance Playnance +35.15%
#9 Nillion Nillion +25.56%
#10 Bitway Bitway +25.33%
Coin of the day
Wrapped One Wrapped One
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Poniard Pharmaceuticals, Inc. Poniard Pharmaceuticals, Inc.

Poniard Pharmaceuticals, Inc.

PARD
Rang in aandelen #42765
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the... Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, such as small cell lung, colorectal, prostate, and ovarian cancers. The company has advanced Picoplatin through several clinical stages, including a pivotal Phase III SPEAR trial for small cell lung cancer patients in a second-line treatment setting. Furthermore, Phase II studies investigated Picoplatin as an initial therapy for metastatic colorectal cancer and hormone-refractory prostate cancer. An early-stage Phase I trial also examined an oral formulation of Picoplatin for solid tumors. Founded in 1984 as NeoRx Corporation, the company rebranded to Poniard Pharmaceuticals, Inc. in September 2006 and operates from its base in Seattle, Washington.
Aandeelprijs
$0.0001
Laatst gesynchroniseerd: 2026-08-11
Marktkapitalisatie
$150.00
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Poniard Pharmaceuticals, Inc. (PARD)

Categorie

Healthcare
Winst voor Poniard Pharmaceuticals, Inc. (PARD)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Poniard Pharmaceuticals, Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Poniard Pharmaceuticals, Inc. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR